The general increase in KDM6A in CML along with the high levels observed in imatinib refractory CML cases proposes that the KDM6A-dependent mechanism of imatinib resistance is also active in patients. The gene discussed is KDM6A; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.